Company
NYSE:LLY
Tirzepatide + oral orforglipron; XPRIZE Healthspan sponsor.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | NYSE |
| Ticker | NYSE:LLY |
| Secondary listing | None |
| Market cap | ~US$1.15T |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
Recent inflection
Oral orforglipron ("Foundayo") FDA-approved 1 Apr 2026.
Latest moves
Keep reading
Sources
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.